(Q39059034)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262875%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262875%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262875%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Pepita Giménez-Bonafé

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262875%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Avelina Tortosa

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262875%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

August Vidal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262875%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Elisabetta Stanzani

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262875%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Roser Mir

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262875%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Fina Martinez-Soler

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262875%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Alberto Villanueva

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262875%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Enric Condom

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262875%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Jordi Ponce

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262875%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

language of work or name

English

0 references

publication date

19 November 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262875%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262875%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

132

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262875%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262875%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

211-220

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24262875%20AND%20SRC:MED&resulttype=core&format=json

Current treatment for ovarian cancer

1 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Survivin, cancer networks and pathway-directed drug discovery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Cancer cells survive with survivin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Anti-apoptosis gene, survivin, and prognosis of neuroblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Validating survivin as a cancer therapeutic target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Effect of shRNA targeting survivin on ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Survivin modulates microtubule dynamics and nucleation throughout the cell cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Poor survival with wild-type TP53 ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013

Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.013